ライフサイエンスコーパス: treated animal

1 reased survival to 30 d (vs. 9 d for vehicle-treated animals).

2 urface (10.3% of the imaging area in vehicle-treated animals).

3 n granulomas and lymph nodes from anti-IL-10-treated animals.

4 nd 101 in slices from naive but not morphine-treated animals.

5 single pegIFNalpha injection in only half of treated animals.

6 eceptor were also increased in the PVN of E2 treated animals.

7 lity, resulting in 100% survival of infected treated animals.

8 itubular capillaritis), were less in the TLN-treated animals.

9 e and were compared with age-matched vehicle-treated animals.

10 nd CD68(+) cells in anti-Netrin-1/anti-Unc5b-treated animals.

11 ithin 7 days compared with 14 days in saline-treated animals.

12 meters more severe in recipients of contrast-treated animals.

13 models classified the two groups control and treated animals.

14 mic viral RNA was detected in two out of six treated animals.

15 follicular helper (Tfh) cells, in belatacept-treated animals.

16 implicating enhanced EDH signalling in BRJ- treated animals.

17 ion in TNF-alpha with respect to non-SET-M33-treated animals.

18 igher regulatory T cell frequencies in FR104-treated animals.

19 e in osteoclasts in anti-Netrin-1/anti-Unc5b-treated animals.

20 19, were both elevated in skin from contrast-treated animals.

21 c, was diminished in DRGs of all natalizumab-treated animals.

22 ration and was continued for 13 weeks in all treated animals.

23 ally cued navigation, when compared with PBS-treated animals.

24 trated elevated levels in the blood of FR104-treated animals.

25 ence in ox-LDL clearance was observed in NAC-treated animals.

26 brain Abeta amyloidosis compared to vehicle-treated animals.

27 CD4(+) T cells recovered from VIPR2 agonist-treated animals.

28 l-treated animals but impairments in vehicle-treated animals.

29 is revealed insignificant changes in the DMA-treated animals.

30 n all infected animals, except dexamethasone-treated animals.

31 ctile response to dobutamine stress than non-treated animals.

32 ease in proteinuria was reduced in UK-396082-treated animals.

33 recovery compared with media- or fibroblast-treated animals.

34 0.0178) at 6 months of age compared to mock-treated animals.

35 ese changes were absent in the dexamethasone-treated animals.

36 ctivated in the extraction wounds of the ALN-treated animals.

37 axons only in the spinal cord dorsal horn of treated animals.

38 fundus red reflex was only found among PF-MC treated animals.

39 nd regeneration scores decreased in Imm-124E treated animals.

40 r were observed in the remote region of cell-treated animals.

41 animals; which were absent in dexamethasone-treated animals.

42 -5 and (18)F-FDG uptake ratios versus saline-treated animals.

43 living animal, was significantly reduced in treated animals.

44 t an enrichment of sCSCs relative to control-treated animals.

45 eriodontal healing process compared with non-treated animals.

46 ation in infected lung tissues for linezolid-treated animals.

47 have been reported to accumulate in hair of treated animals.

48 6 survived significantly longer than control-treated animals.

49 ed by immunohistochemistry for PAS-YNSalpha8-treated animals.

50 engraftment improved by several-fold in ETN-treated animals.

51 s postinjury, compared with control (LV-GFP)-treated animals.

52 ith insignificant differences relative to NS-treated animals.

53 nimals were compared to single mTBI and sham treated animals.

54 differences between control and ABX cocktail-treated animals.

55 rats (left uninflated) compared with vehicle-treated animals.

56 itors significantly decreased weight loss in treated animals.

57 e was also significantly reduced in antibody-treated animals.

58 ymph node cells fell significantly in FTY720-treated animals.

59 in both the 810- and 532-nm micropulse laser-treated animals.

60 cal excretion was also altered in antibiotic treated animals.

61 sone, respectively, in comparison to placebo treated animals.

62 still induced strong responses in the toxin-treated animals.

63 ed animals after 6 weeks relative to vehicle-treated animals.

64 rneal sensitivity and tear secretion in NPD1-treated animals.

65 without changes in A(2A)R expression in PCP-treated animals.

66 omatostatin receptor in slices from morphine-treated animals.

67 both the amoxicillin and ampicillin/neomycin treated animals.

68 ] uptake in the brains of lipopolysaccharide-treated animals.

69 in brain slices from drug-naive and morphine-treated animals.

70 rds of untreated control or SOD/CAT solution treated animals.

71 raised mice, but not germ-free or antibiotic-treated animals.

72 y distal nephron) was highest in telmisartan-treated animals.

73 chondrial respiratory chain observed in sham-treated animals.

74 ns begin to aggregate near the ventricles of treated animals.

75 cognitive dysfunction as was observed in Al-treated animals.

76 eated Sh3tc2-/- mice compared to mock vector-treated animals.

77 h the untreated control and the sIA- and mIV-treated animals.

78 sis in cancer cells and improved survival of treated animals.

79 chromatin- and dendrite-related genes in THC-treated animals.

80 ncreased in CD4-depleted compared to control-treated animals.

81 n did cells exposed to exosomes from control-treated animals.

82 uring free-choice trials in toluene- and air-treated animals.

83 s were upregulated in the PVN and RVLM of E2 treated animals.

84 ansfer of control gut bacteria to antibiotic-treated animals.

85 cytes was increased in CBSC- versus vehicle- treated animals.

86 profound extension of the median survival of treated animals.

87 rating complete responses in the majority of treated animals.

88 were no erosions in anti-Netrin-1/anti-Unc5b-treated-animals.

89 eated, but not in cardiac-derived stem cells-treated, animals.

90 (-457 +/- 152 cells/muL) compared with 5C8H1-treated animals (16 +/- 25, P = 0.037), and the resurgen

91 wered blood sugar levels compared to vehicle treated animals (182.3 +/- 10.4 mg/dl vs. 359.4 +/- 35.8

92 responders and 3 nonresponders among the 10 treated animals); (2) recognize, for each individual sam

93 -TNF and doxorubicin, curing the majority of treated animals (29/37).

94 odulatory subsystem connectivity in ketamine-treated animals, a finding consistent with the known eff

95 mor volume and increased cell death in ErPC3-treated animals accompanied by infiltration of the tumor

96 ster concentrations were lower in WIN 18,446-treated animals, adipose retinyl ester levels were incre

97 esponse to challenge was reduced in antibody-treated animals after 6 weeks relative to vehicle-treate

98 Placebo-treated animals all developed clinical EAE between days

99 , and KLCD150(+)CD48(-) cells from IFN-gamma-treated animals all showed significant upregulation in F

100 ess were all increased in skin from contrast-treated animals-all parameters more severe in recipients

101 Resveratrol-treated animals also displayed increased net neurogenesi

102 A 5-HTT inhibitor, fluoxetine, treated animals also exhibited reduced restenosis after

103 ASGM1-treated animals also exhibited significant pulmonary art

104 Toluene-treated animals also had decreased mPFC activity during

105 rescued myelin levels compared with vehicle-treated animals and also regulated astrocyte and microgl

106 oped on the tongues and esophagi of the 4NQO-treated animals and included hyperkeratoses, papillomas,

107 o-expression networks common to both the THC-treated animals and patients with schizophrenia were enr

108 OP was raised 10 mmHg for weeks-to-months in treated animals and unaltered in control animals.

109 nificantly, tumour growth was impaired in C4-treated animals and vascular density was also reduced in

110 omes between sites, between reference and E2-treated animals, and between FSH-treated and nontreated

111 e (MMP), and Furin inhibitors in Antimycin A-treated animal as well as in the C. elegans Duchenne mus

112 tly decreased in the prostatic epithelium of treated animals as compared to controls.

113 protein levels were markedly reduced in BBR-treated animals as compared with the control.

114 Visual function was partially restored in treated animals, as evidenced by two visual behavioral t

115 ession was suppressed by 65-92% in capsaicin-treated animals, as was epinephrine (74%), norepinephrin

116 cral gray matter in the anti-Nogo-A antibody-treated animals, as well as a reduced number of inhibito

117 3 were also observed in neomycin- or neamine-treated animal ascitic cells.

118 treated animals compared to SLPI and buffer-treated animals at 18 hours and 24 hours postinjury.

119 was observed in the plasma of 67% of the ART-treated animals at 7 weeks after ART interruption, and n

120 ly less paw lymphedema compared with vehicle-treated animals at all time-points (P < 0.001).

121 icantly different between rGDF11 and vehicle-treated animals at baseline and remained unchanged at 1,

122 of viable tumor tissue in (177)Lu-DOTA-JR11-treated animals, at 6.2% (IQR, 2%-23%).

123 L-10 expression and IL-10/TNF-alpha ratio in treated animals before MI.

124 In treated animals, blood vessel perfusion was improved and

125 ing, memory and mood function in resveratrol-treated animals but impairments in vehicle-treated anima

126 er than those before ART initiation in IL-21-treated animals but not in controls.

127 ecombinant tissue-type plasminogen activator-treated animals, but enduring high thrombus activity in

128 rapidly reversed fatal liver failure in CCl4-treated animals by restoring diseased hepatocytes rather

129 s an upregulation of M2 macrophages in laser treated animals by the increasing number of double label

130 Moreover, tolerized DCs from sulfatide-treated animals can adoptively transfer protection into

131 antibiotics residues that are excreted from treated animals can contribute to persistence of resista

132 icroglia derived from germfree or antibiotic-treated animals cannot stimulate viral-specific immunity

133 Moreover, in DAR-treated animals, cell transplantation-induced activation

134 icant improvements in rotarod performance in treated animals compared to AAV2.9-MCK-eGFP-treated mice

135 veloped faster in paclitaxel and vincristine treated animals compared to cisplatin and bortezomib tre

136 were not significantly enhanced in the bnAb-treated animals compared to control animals, arguing aga

137 nd BWT scores were noted in CT images of MSC-treated animals compared to placebo-treated cats at mont

138 erated area was significantly lower in PF-MC treated animals compared to SLPI and buffer-treated anim

139 inal function, and retinal morphology in PBM-treated animals compared to the sham-treated group.

140 of pulmonary CD8(+) T lymphocytes in rhIL-7-treated animals compared to those in untreated mice.

141 low (CBF) significantly improved in IRL-1620-treated animals compared to vehicle by day 7 post MCAO.

142 to detect preserved systolic function in EHM-treated animals compared with control (control 4.4+/-1.0

143 erall BDNF levels in the hippocampus of drug-treated animals compared with control animals.

144 r in conventional mice, but was higher in AB-treated animals compared with controls.

145 was achieved in the lipopolysaccharide (LPS)-treated animals compared with healthy controls (p<0.001)

146 nding protein (pCREB) in the CA1s of a-FMHis-treated animals compared with in controls.

147 essels significantly increased in fibrinogen-treated animals compared with sham (77% vs 18%).

148 ctivation occurred earlier in cyclosporine A-treated animals compared with those receiving rapamycin.

149 In addition, lesions in 2DG-treated animals contained less proinflammatory effectors

150 After 12 hours, the saline-treated animals (controlled mechanical ventilation) and

151 Unlike PTU-treated animals, crystal larvae are able to perform visu

152 In comparison to untreated controls, GH-treated animals demonstrated enhanced median nerve regen

153 In addition, treated animals demonstrated increased expression of syn

154 ed region of the spinal cord of nano-SOD/CAT-treated animals demonstrated significantly reduced mitoc

155 IBF-treated animals demonstrated subsequent disruption of th

156 None of the C3 -treated animals developed any toxicity.

157 However, none of the treated animals developed TB reactivation disease, and t

158 FR104-treated animals did not develop clinical EAE and were sa

159 tant acute cellular rejection, whereas FR104-treated animals did not.

160 In addition, adolescent MAM-treated animals displayed a blunted HPA axis corticoster

161 pressure acutely in all animals, VEGFCc156s-treated animals displayed a delayed systemic reduction i

162 NR1 AB-treated animals displayed increased early postnatal mort

163 lls isolated from anti-CD4 versus control Ab-treated animals displayed increased in vitro chemotaxis

164 hanics and histology between control and VNS-treated animals during HF development.

165 o University of Wisconsin-treated and saline-treated animals, especially in skin and muscle when CI t

166 in antibody-treated than in control antibody-treated animals, even though IFN-gamma and NOS2 mRNA lev

167 ing IV administration of doxorubicin, MRgFUS-treated animals exhibited a 4-fold higher concentration

168 Only 2C10R4-treated animals exhibited a modest, transient drop in CD

169 In addition, the DHA-treated animals exhibited early recovery of their sensor

170 Remdesivir-treated animals exhibited improved clinical scores, lowe

171 At 2 and 4 weeks after injury, Ad-p27-126TS-treated animals exhibited reduced restenosis, complete r

172 Both groups of cell-treated animals exhibited significantly reduced scar siz

173 erent levels between control and pilocarpine-treated animals for 27 miRNAs.

174 Importantly, baricitinib-treated animals had a rapid and remarkably potent suppre

175 KYP-2047-treated animals had a significantly decreased amount of

176 In addition, hMSC-treated animals had a significantly lower cumulative req

177 is revealed that clopidogrel- and ticagrelor-treated animals had a significantly smaller extent of MI

178 f NMT1 reduced tumor growth, and tumors from treated animals had increased apoptosis and displayed ma

179 9-cis RA-treated animals had less early postsurgical edema and si

180 Erlotinib-treated animals had less histological glomerular injury

181 After 6 months, Ang 1-7-treated animals had lower body weight (-9.5%), total fat

182 At necropsy, remdesivir-treated animals had lower lung viral loads and reduced l

183 ogy, blood chemistry and coagulopathy, siRNA-treated animals had milder clinical features and fully r

184 Compared with untreated animals, UK-396082-treated animals had reduced glomerular and tubulointerst

185 stages of infection, Mtb infected metformin-treated animals had restored systemic insulin sensitivit

186 CES-treated animals had significantly accelerated nerve rege

187 9-cis RA-treated animals had significantly faster lymphatic drain

188 Chemotherapy-treated animals had significantly fewer offspring compar

189 rhTSG-6-treated animals had significantly less MPO (P = 0.027) a

190 d with controls, carfilzomib- and belatacept-treated animals had significantly prolonged graft surviv

191 In the phosphate buffered saline-treated animals, human skin allografts were infiltrated

192 All treated animals in studies 1 and 2 were protected, consi

193 lasma cytokines were also attenuated in IL-6-treated animals, including significant reductions in TNF

194 rove episodic spatial memory relative to oil-treated animals, indicating closing of the critical wind

195 stance emergence was assessed in oseltamivir-treated animals infected with wild-type virus; emergence

196 w the improved phenotype of the Cu(II)(atsm)-treated animals involves an increase in mature mutant SO

197 Hearing acuity in treated animals is unaltered at postnatal day 30.

198 The MiPSC-treated animals lacked any evidence of de novo cardiac d

199 observed in HIF prolyl-hydroxylase inhibitor-treated animals lacking endothelial HIF-2.

200 Combination-treated animals live as long as their non-engrafted litt

201 , in another study, that all of the antibody-treated animals lived, whereas 3/8 phosphate-buffered sa

202 Unlike vehicle-treated animals, macaques treated with remdesivir did no

203 ) T lymphocytes from Mtb infected, metformin treated animals maintained a more normal mitochondrial m

204 ot significantly differ between infected and treated animals, microbial dysbiosis was evident via mul

205 8) and was not detected in any of the saline treated animals (N = 6).

206 In contrast, in methadone- or buprenorphine-treated animals no respiratory depression was observed w

207 Remarkably, treated animals not only demonstrated reductions in glyc

208 Hippocampal sections from JNJ-47965567-treated animals obtained >5 d after treatment ceased dis

209 significantly different between control and treated animals over time in the region of low stress.

210 in the MR imaging-guided focused ultrasound-treated animals (P < .01).

211 timal thickness between rejecting and AD-MSC-treated animals (P < 0.01).

212 n control animals compared to RvD2- and RvD1-treated animals (P < 0.05), resulting in a reduction of

213 myocardium of ticagrelor- versus clopidogrel-treated animals (P<0.05).

214 On both tests, E-treated animals performed better than the other 3 experi

215 y, residual disease severity in the CD20 mAb-treated animals positively correlated with the frequency

216 ingly, blood-glucose-levels drop severely in treated animals, presumably due to glucose consumption.

217 When sorafenib-treated animals received metoprolol treatment post MI, t

218 Furthermore, m21G6-treated animals recovered 85.4% of their baseline left v

219 The lymph nodes of the control treated animals regressed in size and their nodal struct

220 were reduced by ca 40% in tumours from MM41-treated animals relative to controls, consistent with BC

221 Gene therapy increased the life span of treated animals, rescued the lethal neurodegeneration, n

222 epress respiration but in prolonged morphine-treated animals respiratory depression was observed when

223 Virotherapy of cyclophosphamide-treated animals resulted in sustained viral infection wi

224 fill at day 10 as compared with the vehicle-treated animals, resulting in less buccal plate resorpti

225 Th17 cells in the lamina propria of ITF2357-treated animals, resulting in the amelioration of diseas

226 Furthermore, hepatocytes of UDCA-treated animals retained their metabolic activity as evi

227 orsal root ganglion neurons from vincristine-treated animals revealed a significant upregulation of T

228 myelinated sciatic nerves from pioglitazone-treated animals revealed an unanticipated increase in ge

229 All treated animals revealed peripheral blood chimerism (4 w

230 of mRNA expression and protein levels in ESA-treated animals revealed reduced matrix metalloproteinas

231 After hemodilution, treated animals show higher arterial blood pressure and

232 Moreover, the small intestine of treated animals show reduced hypoxic injury compared to

233 In addition, PCP-treated animals showed a significant reduction of striat

234 Treated animals showed a significant slowing of the prog

235 Stimulation-treated animals showed a twofold increase in synaptic de

236 against biologically relevant radicals, and treated animals showed decreased neutrophil influx and N

237 Ad-3Delta-A20T-treated animals showed higher viral genome copy numbers

238 bens (NAc) following CPP expression, cocaine treated animals showed increased phosphorylated ERK (pER

239 MDMA treated animals showed increased uncoupling protein 1 (U

240 Moreover, treated animals showed lower levels of systemic (serum)

241 NA through an adeno-associated viral vector, treated animals showed marked improvements in both globa

242 Viral RNA isolated from treated animals showed reduced infectivity, a feature of

243 ore, nesting tests demonstrated that the ELP-treated animals showed significant neurobehavioral defic

244 Furthermore, annexin A5-treated animals showed significant reductions in myocard

245 istochemical analyses of the spinal cords of treated animals showed significantly lower ROS, cleaved

246 d complement-mediated bacteriolysis, whereas treated animals showed slightly improved bacterial clear

247 lls from PF-06747143-treated or IgG1 control-treated animals showed that leukemic progenitors were al

248 Finally, in PCP-treated animals, sub-chronic administration of haloperid

249 x) was significantly decreased in antibiotic treated animals suggesting decreased bioavailability.

250 tion was enhanced by P-gp inhibitors in APAP-treated animals, suggesting P-gp-mediated transport.

251 ation in tissue from both naive and morphine-treated animals, suggesting that GRK2/3 remained active.

252 and decreased neurological deficit scores in treated animals, supporting the next preclinical studies

253 on in axon arbor complexity seen in d-serine-treated animals, tectal neuron visual receptive fields w

254 gnificantly more primordial follicles in MIS-treated animals than in controls.

255 In treated animals that became infected, the GALT was signi

256 (11)C-PK11195 was elevated in dexamethasone-treated animals that had shown mild clinical symptoms th

257 is occurred also in lipopolysaccharide (LPS)-treated animals that mimic inflammation, as well as afte

258 tion revealed a strong fluorescent signal in treated animals that was equivalent to BMP-2.

259 cted untreated animals away from healthy and treated animals that were clustered closely, indicating

260 However, in slices taken from morphine-treated animals, the combination of these blockers along

261 intained weight and low lung viral titers in treated animals, the passive transfer of a nAb provides

262 Importantly, for BDNF-treated animals, these eCAP characteristics were near no

263 nfiltration in the periodontium than vehicle-treated animals; these actions were associated with redu

264 In the cell-treated animals, this late adverse LV remodeling was att

265 mals with EP treated with water; G3-Losartan-treated animals (treatment started at the same day of EP

266 PEGPH20-treated animals uniformly displayed clear reductions in

267 perilesional reorganization in stimulation- treated animals versus SHAM.

268 sis in activated CD4(+) T cells, and renders treated animals vulnerable to TB reactivation and reinfe

269 The overall effect observed in CSC-treated animals was 10.7% (95% confidence interval 9.4-1

270 ds, and the rate of cell engraftment in hCMP-treated animals was 24.5% at week 1 and 11.2% at week 4.

271 hat changes in microbe content in antibiotic treated animals was associated with changes in acetamino

272 ficant (p < 0.05) demyelination in cuprizone-treated animals was found according to both LFB staining

273 VH3 clan IgG from S. aureus-infected or SpA-treated animals was not pathogen-specific, suggesting th

274 In EE and IGF-1-treated animals, we assessed the hippocampal expression

275 In PGT121-treated animals, we detected low levels of viral RNA and

276 TPH1-deficient and TPH1-inhibitor-treated animals were challenged in ovalbumin and house d

277 result, it was found that medicated and non-treated animals were clearly clustered in distinct group

278 to humans, HIV-1 levels in the blood of ART-treated animals were frequently suppressed below the lim

279 e due to suppression of IFN-gamma, linezolid-treated animals were given intranasal instillations of r

280 However, when corticosterone-treated animals were pair-fed to control intake, aiming

281 l 6 controls were infected, while the 6 PrEP-treated animals were protected from infection.

282 Tumors from PnV-treated animals were smaller and did not uptake detectab

283 epatic lymphocytes from IFN-alpha- and IL-15-treated animals were transferred to new HBV carriers, pa

284 production compared to the control antibody treated animals, whereas a change in gob5 gene expressio

285 and diastolic strain only in the combination-treated animals, which also exhibited increased cardiomy

286 s remained elevated within the BAL fluids of treated animals, which was consistent with the fungal bu

287 of the cagY gene of output strains from DFMO-treated animals, which were associated with alterations

288 e production in H2 R-deficient or famotidine-treated animals, while dimaprit dampened the lung iNKT c

289 ed the intestinal microbiota of streptomycin-treated animals, while vancomycin promoted the expansion

290 rate was significantly suppressed in MRgFUS-treated animals whose tumours also exhibited decreased K

291 Survival was significantly improved in Cpt-treated animals with a survival benefit visible as soon

292 We included 4 experimental groups: vehicle-treated animals with extraction of healthy teeth or teet

293 eth or teeth with ligature-induced EP and ZA-treated animals with extraction of healthy teeth or teet

294 We treated animals with fluoxetine and induced ovulation wi

295 onatal C57BL/6 or C3H mice with H. pylori or treated animals with H. pylori components (bacterial lys

296 Control animals were injected with water and treated animals with rimcazole (26 mg/kg) in water.

297 te responses were observed for the DOTA-PRIT-treated animals within 30 d.

298 in HCV viremia was observed in one of three treated animals without apparent hepatocellular injury.

299 uctions ranging from 46 to 55% in 38% of the treated animals without causing any toxic side effects.

300 d in CLR01-treated mice, relative to vehicle-treated animals, yet motor function did not improve in a